AGA2115

About Angitia Biopharmaceuticals

Angitia Biopharmaceuticals is a private, clinical-stage biotech with a focused pipeline of three biologic candidates targeting high-need musculoskeletal conditions, including osteoporosis and osteogenesis imperfecta. The company is led by industry veteran Dr. Hua Zhu (David) Ke, who previously contributed to the development of blockbuster bone drugs like Prolia and Evenity. With a strong financial position bolstered by a recent $130M Series D round in 2026, Angitia is advancing multiple Phase 2 trials globally while building on a foundation of proven scientific acumen in bone biology.

Therapeutic Areas

Other Osteogenesis Imperfecta Drugs